If you’ve seen the SPIVA numbers calling out active investors, pointing our how short they fall in comparison to owning simple index funds, and yet, the urge to identify and invest in top small-cap stocks still remains strong, the least you can do is diversify.
This article is disseminated in partnership with Seraphim Space Investment Trust PLC and BSF Enterprise PLC. It is intended to inform investors and should not be taken as a recommendation or financial advice.
By this I mean, spread your risk across a handful of positions, expecting that your due diligence will fail – probably as much as it succeeds – leaving enough room for value creation to outweigh value destruction by the time your financial goals call for an asset sale.
Now, while there are different schools of thought about how many single stocks you should own, there are strong reasons for this number to be, at minimum, in the double digits, allowing you to build exposure across industries and a fuller breadth of economic activity.
That said, it can be difficult for a stock picker to properly diversify within a given industry, given the intellectual fuel required to research and follow 10 technology stocks, for example, which would be required to preserve the potentially exponential upside single stocks offer, versus an index fund’s hundreds or thousands of positions, which ditch differentiated returns in favor of broad market diversification.
Luckily for you, the small-cap space is well-populated with stocks with diversification at their core, allowing you to lock in de-risked exposure to their target markets by owning a single ticker, saving you endless hours of due diligence.
Seraphim Space Investment Trust
We kick off the latest edition of Weekly Market Movers with Seraphim Space Investment Trust, market cap £424 million, the world’s first public fund dedicated to space technology, ideally positioning investors to capitalize on a US$469 billion sector expected to surpass the trillion-dollar mark by the end of the decade.
Launched in 2021 with a focus on companies turning science into functional businesses, Seraphim has built a 19-piece portfolio brimming with the potential for global dominance in the areas of security, cybersecurity, food security, climate change and sustainability. Here are three standout names:
- ICEYE, owner the world’s largest and most advanced synthetic aperture radar satellite constellation, allowing institutions to more accurately track natural hazards and catastrophes from any point on Earth.
- D-ORBIT, an in-space services provider specializing in space logistics, space waste management and orbital transportation, including the last-mile delivery of satellites.
- HawkEye360, whose satellite constellation is able to track and analyze radio frequency signals, including an initial use-case identifying illegal fishing vessels.
A decorated leadership team, including chair, Will Whitehorn, who served as president of Virgin Galactic, and CEO, Mark Boggett, who has invested in three companies that went on to achieve billion-dollar valuations, has placed Seraphim in a comfortable position to build value into the future, supported by £56.4 million in capital gains in 2025, up from £11.5 million in 2024, £22.1 million in cash as of December 2025 to put to work, 70 per cent of the portfolio fully funded and 85 per cent expecting to reach EBITDA profitability in 2026.
This setup is imbuing 2026 with notable optimism, driven by increased defense-related spending across the Western world, as well as renewed interest in space technology stemming from SpaceX’s upcoming public listing, prompting Whitehorn to state in the company’s interim 2025 report that “the board remains confident that the year ahead will build further on the progress achieved to date and that 2026 has the potential to exceed the levels of performance recorded last year.”
Shares of Seraphim Space Investment Trust (LSE:SSIT) have added 258 per cent year-over-year, last trading at £179.
James Bruegger, Seraphim’s chief investment officer, sat down with Stockhouse’s Ricki Lee to discuss the major tailwinds propelling space technology. Watch the interview here.
BSF Enterprise
From the outer reaches of space, we shift to the microscopic world of cell-based tissue engineering with BSF Enterprise, market cap £2.92 million, a company focused on sustainable alternatives to finite resources, including animal and human tissues. Here’s a breakdown of BSF’s portfolio:
- 3D Bios Tissues (3DBT) supplies cell and tissue culture media additives for both upstream and downstream clients, helping to reduce costs while improving yield and functionality.
- Lab Grown Leather (LGL) specializes in cultivated leather materials that blend aesthetics, functionality and a radically reduced environmental footprint.
- Kerato offers artificial hydrogel-based tissue for the purposes of corneal repair in both clinical and veterinary settings.
- Cultivated Meat Technologies is developing artificial meat using 3DBT supplements with a focus on low costs, high protein and scalability.
Through these diversified verticals, BSF is leading the charge when it comes to reversing livestock farming’s environmental harm, which accounts for 24 per cent of the world’s greenhouse gas emissions, 33 per cent of water use and 66 per cent of antibiotic use, according to the company’s December 2025 investor deck. In so doing, BSF is addressing target markets collectively valued in the hundreds of billions, each of which is in dire need of more sustainable practices to compete on the global stage.
When it comes to putting this plan into practice, BSF boasts a bespoke leadership team, including CEO, Dr. Che Connon, a world-renown expert in tissue engineering who has more than 20 years of experience in extracellular biology, and CSO, Ricardo Gouveia, who has been innovating in stem cell biology and tissue bio-fabrication for nearly 20 years, optimally qualifying the company to capitalize on numerous value inflection points lined up over the next 18 months. These include:
- A £300,000 cultivated meat additive supply agreement between 3DBT and SeaWith, a pioneering South Korean biotechnology company.
- LGL’s launch of the world’s first handbag made from lab-grown leather. Dr. Connor and chair, Geoff Baker, joined Ricki Lee to discuss. Watch the interview here.
- Kerato’s upcoming liquid cornea veterinary trial, 50 per cent funded by the Canadian government, to support market penetration and medical device advancement.
- Ongoing M&A discussions with target companies developing complementary technologies.
With BSF actively accelerating portfolio growth, investors haven’t been shy about throwing their weight behind the company, lifting BSF stock (LSE:BFSA) by 35.51 per cent year-over-year. Concurrently, the company’s diminutive size and share price, last trading at £1.74, make for a compelling entry point as it vies to marry shareholder value and environmental conservation in some of the world’s most essential industries.
Thanks for reading! I’ll see you next Monday for a new edition of Weekly Market Movers, where I delve into companies that sat down with Stockhouse for an interview over the past week. Here’s the most recent article, in case you missed it.
Join the discussion: Find out what investors are saying about these top small-cap stocks on the Seraphim Space Investment Trust PLC and BSF Enterprise PLC Bullboards, and make sure to explore the rest of Stockhouse’s stock forums and message boards.
